Trigonella Foenum Graecum Seed Extract Attenuated the hs‐ CRP Level in Patients With Myocardial Infarction: A Randomized, Triple‐Blind, Placebo‐Controlled Clinical Trial

ABSTRACT This investigation was conducted to explore the effects of Trigonella foenum‐graecum L. (fenugreek) seed extract, an anti‐inflammatory herbal extract, on reducing inflammation in patients diagnosed with myocardial infarction (MI). For this triple‐blind, randomised clinical study, patients with MI were split into two groups within the first 24 h. One group took fenugreek seed extract tablets twice daily ( N = 28), while the other took placebo tablets twice daily ( N = 26). After 4 weeks of treatment, we measured CBC‐diff, high‐sensitivity C‐reactive protein (hs‐CRP) and lipid profiles. The tablets containing fenugreek seed extract (Glucurex B, 335 mg) were obtained from Barij Essence Company. The extract was standardised, showing luteolin at 0.02% w/w and 4‐Hydroxyisoleucine at 1.04% w/w. No remarkable differences were observed in demographic characteristics and baseline laboratory parameters between the two groups. Data analysis showed significant reductions in hs‐CRP ( p < 0.001), low‐density lipoprotein (LDL) ( p = 0.032, p = 0.02) and cholesterol ( p < 0.001, p = 0.032) in both the fenugreek and placebo groups after 4 weeks. Moreover, hs‐CRP amounts were notably lower in the fenugreek group compared to the placebo group after a four‐week treatment period ( p = 0.001). Furthermore, the differences in hs‐CRP levels before and after treatment were considerably more pronounced in the fenugreek group (0.95 [3.18]) than in the placebo group (0.6 [0.94], p = 0.02). The administration of fenugreek to MI patients provides additional anti‐inflammatory and lipid‐modifying effects beyond standard treatment. These advantages, from a natural product with a known safety profile, could open new avenues for future cardiovascular disease treatment research. However, the long‐term effects require confirmation through large‐scale, long‐term clinical studies. Trial Registration: ClinicalTrials.gov identifier: IRCT20220516054874N9